Literature DB >> 18163518

The effects of rituximab on immunocompetency in patients with autoimmune disease.

R John Looney1, Renganathan Srinivasan, Leonard H Calabrese.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18163518     DOI： 10.1002/art.23171

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  22 in total

1.  Indications of rituximab in autoimmune diseases.

Authors:  Iñaki Sanz
Journal:  Drug Discov Today Ther Strateg       Date:  2009-04-01

Review 2.  Does rituximab increase the incidence of infectious complications? A narrative review.

Authors:  Theodoros Kelesidis; George Daikos; Dimitrios Boumpas; Sotirios Tsiodras
Journal:  Int J Infect Dis       Date:  2010-11-11       Impact factor: 3.623

Review 3.  Immunomodulatory approaches to the management of chronic urticaria: an immune-mediated inflammatory disease.

Authors:  Clifton O Bingham
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.806

4.  Fulminant toxic shock syndrome following rituximab therapy in an 11-year-old boy.

Authors:  Nolwenn Le Saché; Mickael Afanetti; Kumaran Deiva; Laurent Chevret; Pierre Tissières
Journal:  J Neurol       Date:  2013-09-20       Impact factor: 4.849

Review 5.  Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.

Authors:  Ronald P Taylor; Margaret A Lindorfer
Journal:  Curr Opin Immunol       Date:  2008-07-01       Impact factor: 7.486

Review 6.  B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data.

Authors:  R John Looney
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

7.  B cell depletion for autoimmune diseases in paediatric patients.

Authors:  Annette F Jansson; Claudia Sengler; Jasmin Kuemmerle-Deschner; Bernd Gruhn; A Birgitta Kranz; Hartwig Lehmann; Daniela Kleinert; Lars Pape; Hermann J Girschick; Ivan Foeldvari; Dieter Haffner; Johannes P Haas; Dagmar Moebius; Dirk Foell; Joachim Peitz; Veit Grote
Journal:  Clin Rheumatol       Date:  2010-12-01       Impact factor: 2.980

8.  CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.

Authors:  Roman Puliaev; Irina Puliaeva; Lisbeth A Welniak; Abigail E Ryan; Mark Haas; William J Murphy; Charles S Via
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

Review 9.  Rationale of using different biological therapies in rheumatoid arthritis.

Authors:  Matthias Geyer; Ulf Müller-Ladner
Journal:  Arthritis Res Ther       Date:  2010-08-24       Impact factor: 5.156

Review 10.  B cells in the pathogenesis and treatment of rheumatoid arthritis.

Authors:  Bethany Marston; Arumugam Palanichamy; Jennifer H Anolik
Journal:  Curr Opin Rheumatol       Date:  2010-05       Impact factor: 5.006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.